The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The label for Moderna's respiratory syncytial virus (RSV) vaccine mResvia has been expanded to include adults aged 18 and over in the US, widening its earlier FDA approval for the over-60s only.

Moderna plans to make mRESVIA available in the U.S. for the 2025-2026 respiratory virus season for high-risk adults ages 18 to 59 and all adults age 60 or older. Patients should tell their health ...

Moderna’s shares dipped slightly on the approval announcement, likely due to that revised efficacy, according to analysts at William Blair. mResvia’s top-line score comes in slightly lower ...

Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted UK pharma major GSK’s regulatory application to expand the ...

The Moderna vaccine is one of the vaccines currently available in the United States and other countries to protect against COVID-19, which is the disease the novel coronavirus causes. Clinical ...